Who
Magda Marquet
Director
Company insider
Files Form 4 as: Director, First Tracks Biotherapeutics; Director, Arcturus Therapeutics Holdings; Director, Immix Biopharma; Director, AnaptysBio; Director, TransCode Therapeutics; Director, Pfenex.
In numbers
- Trades disclosed
- 91
- Buys
- 5
- Sells
- 1
- Bought
- $113K
- Sold
- $1.1M
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 28 Feb 2019
- Last trade
- 15 Jun 2026
- Last filed
- 17 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | TRAX First Tracks BiotherapeuticsBiotechnology | SEC FORM 4 Code M | —6,030 at $0.00 | filing |
| 5 Jun 2026filed 15 Jun 2026 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 5 Jun 2026filed 15 Jun 2026 | ARCT Arcturus Therapeutics Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 22 May 2026filed 29 May 2026 | IMMX Immix BiopharmaBiotechnology | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 22 May 2026filed 29 May 2026 | IMMX Immix Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 22 May 2026filed 29 May 2026 | IMMX Immix Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 22 May 2026filed 29 May 2026 | IMMX Immix BiopharmaBiotechnology | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 12 May 2026filed 12 Jun 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —784 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
News
Financial Review: Myriad Genetics (NASDAQ:MYGN) & AnaptysBio (NASDAQ:ANAB)ANAB · tickerreport.com · 20 Oct 2026
0 headlines in the last 90 days name Magda Marquet; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.